<DOC>
	<DOCNO>NCT00753688</DOCNO>
	<brief_summary>A randomized double blind phase III trial Pazopanib versus placebo patient soft tissue sarcoma whose disease progress follow prior therapy</brief_summary>
	<brief_title>Pazopanib Versus Placebo Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During Following Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Inclusion/ High intermediate grade soft tissue sarcoma ; Low grade tumour allow provided disease progression . Metastatic measurable disease ( RECIST ) ; Subjects receive maximum 4 prior line systemic therapy ( include 2 combination regimen ) advance disease . ( Neo ) adjuvant/maintenance treatment count criterion ; Last dose prior therapy give upto 14 day prior start study ongoing toxicity prior anticancer therapy grade 1 resolve ( except alopecia ) . Must fail anthracyclinebased therapy available standard chemotherapy treat institution except medically contraindicate refused patient ; No treatment antiangiogenesis inhibitor ; Age &gt; 18 year WHO PS 01 ; No leptomeningeal brain metastasis , normal bone marrow , liver , renal cardiac function ; No prior history malignancy sarcoma ( except basal cell squamous cell carcinoma skin carcinoma insitu cervix breast patient free malignancy &gt; 3 year ) Adequate bone marrow function ; adequate blood clot result ; adequate hepatic renal function ; No poorly control hypertension ; Clinically normal cardiac function ; No clinically significant gastrointestinal abnormality include malabsorption syndrome , major resection stomach small bowel could affect absorption study drug , active peptic ulcer disease , inflammatory bowel disease , ulcerative colitis , gastrointestinal condition increase risk perforation , history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day prior begin study treatment . No cerebrovascular accident 1 No transient ischemic attack , deep vein thrombosis pulmonary embolism within past six month ; No active bleed bleeding diathesis ; No hemoptysis within six week study drug ; No major surgery trauma within 28 day therapy treatment ; Concomitant medication restriction ; No know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib Ability swallow &amp; retain oral medication Adequate contraception must use ; No Psychological familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition assess patient randomization trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>metastatic soft-tissue sarcoma</keyword>
	<keyword>pazopanib</keyword>
	<keyword>Soft Tissue Sarcoma</keyword>
	<keyword>placebo</keyword>
</DOC>